ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Irinotecan sucrosofate is on this study

  • The record lists it as a treatment, written “Nal-IRI”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 2, 2026, 3:40 AM UTC
  • The role rule says the same.
  • So Irinotecan sucrosofate's page lists this study under “Testing it”.
7 links0 made here, not in the record13 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT04150640Oxaliplatin and LiposomalIrinotecan (PlusTrastuzumab forHER2-positive Disease) inAdvanced Esophageal andGastric AdenocarcinomaUniversity of Wisconsin, MadisPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSAdenocarcinoma Of EsophagusThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSIrinotecan sucrosofateEntry “Nal-IRI”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedOxaliplatinIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedFluorouracilEntry “5-FU”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · establishedNov 18 · Rule based · BackgroundBackground · establishedPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2Irinotecan sucrosofateClaude Opus 5.5TestedCurrent
Nov 2OxaliplatinClaude Opus 5.5TestedCurrent
Nov 2FluorouracilClaude Opus 5.5TestedCurrent
Nov 2TrastuzumabClaude Opus 5.5Background · establishedCurrent
Nov 2PembrolizumabClaude Opus 5.5TestedCurrent
Nov 2NivolumabClaude Opus 5.5TestedCurrent
Nov 18Irinotecan sucrosofateRule based · role ruleTestedAgrees
Nov 18OxaliplatinRule based · role ruleTestedAgrees
Nov 18FluorouracilRule based · role ruleTestedAgrees
Nov 18TrastuzumabRule based · role ruleBackgroundAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundOverridden
Nov 18NivolumabRule based · role ruleBackgroundOverridden
As of nowAdenocarcinoma Of EsophagusRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.